A novel solid dosage form of rifampicin and isoniazid with improved functionality.
The aim of the present investigation was to develop a novel dosage form of rifampicin and isoniazid to minimize degradation of rifampicin in acidic medium and to modulate the release of rifampicin in the stomach and isoniazid in the intestine. Gastroretentive tablets of rifampicin (150 mg) were prepared by the wet granulation method using hydroxypropyl methylcellulose, calcium carbonate, and polyethylene glycol 4000. The granules and tablets of rifampicin were characterized. Hard gelatin capsules (size 4) containing a compacted mass of isoniazid (150 mg) and dicalcium phosphate (75 mg) were enteric coated. Two tablets of rifampicin and 1 capsule (size 4) of isoniazid were put into a hard gelatin capsule (size 00). The in vitro drug release and in vitro drug degradation studies were performed. Rifampicin was released over 4 hours by zero-order kinetics from the novel dosage form. More than 90% of isoniazid was released in alkaline medium in 30 minutes. The results of dissolution studies with the US Pharmacopeia XXIII method revealed that a substantial amount of rifampicin was degraded from the immediate release capsule containing rifampicin and isoniazid powder owing to drug accumulation in the dissolution vessel and also to the presence of isoniazid. The degradation of rifampicin to 3-formyl rifampicin SV (3FRSV) was arrested (3.6%-4.8% degradation of rifampicin at 4 hours) because of the minimization of physical contact between the 2 drugs and controlled release of rifampicin in acidic medium in the modified Rossett-Rice apparatus. This study concludes that the problem of rifampicin degradation can be alleviated to a certain extent by this novel dosage form.
Gohel
Mukesh C
MC
Department of Pharmaceutics, L. M. College of Pharmacy, Navrangpura, Gujarat, Ahmedabad, India. mukeshgohel@hotmail.com
Sarvaiya
Krishnakant G
KG
D000995:Antitubercular Agents / Q000008:administration & dosage*; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D007538:Isoniazid / Q000008:administration & dosage* / Q000737:chemistry; D012293:Rifampin / Q000008:administration & dosage* / Q000737:chemistry; D012995:Solubility; D013607:Tablets; D013608:Tablets, Enteric-Coated
D000995:Antitubercular Agents; D002214:Capsules; D013607:Tablets; D013608:Tablets, Enteric-Coated; D007538:Isoniazid; D012293:Rifampin